Narayana Hrudayalaya Limited
NH
Quarterly Score
Showing the latest 12 quarterly points (newest to oldest).
Score context (latest 12 quarters)
No additional context available.
No additional context available.
No additional context available.
No additional context available.
No additional context available.
No additional context available.
No additional context available.
No additional context available.
No additional context available.
No additional context available.
Cayman hospital expects 'a couple of quarters of growth left before it starts to moderate' to high single-digits. Insurance business growth is substantial with 'room to grow,' but management will take a 'calibrated call' on its long-term scale and cautions against short-term breakeven predictions due to underwriting volatility. India clinics and insurance businesses are expected to continue declining losses, aiming for a 'much lower loss number for FY27'. Mumbai hospital is anticipated to turn 'positive Q3'. 100 new beds in Bangalore are 'progressing as planned' and 'should be able to commission by Q1 of FY26'.
Quarter summary
- Successful strategic shift towards high-value services, case-mix, and payer-mix optimization driving profitability and efficiency in the India operations.
- Rapid expansion and strong market capture in the Cayman Islands, particularly within new hospital services and employer-sponsored insurance product offerings.
Rationale
- Cayman business (HCCI) achieved exceptional revenue growth of 70% overall, with insurance revenue doubling quarter-on-quarter, demonstrating strong market penetration and product reception.
- Cayman hospital maintains high operating margins of 40-43% and is expected to continue growth for another 'couple of quarters' before moderation, with ongoing efforts to optimize cost structure.
Management expects the acquisition to be EPS neutral to mildly favorable in the first year post-acquisition (FY26). A conservative base case ROCE target of 20-22% is set for FY29-30. There is an intention to improve the revenue trajectory and earnings of PPG Hospitals.
Quarter summary
- Narayana Hrudayalaya (NH) is making a strategic entry into the UK private healthcare market through the acquisition of Practice Plus Group Hospitals Limited (PPG Hospitals).
- The core strategy is to replicate NH's successful operational efficiency model from the Cayman Islands to improve PPG's cost structure and increase profitability, while also diversifying its payor mix.
Rationale
- The acquisition of Practice Plus Group Hospitals (PPG) is on a debt-free basis for the acquired entity, eliminating a significant liability burden for the target as the seller repays existing term loans.
- Management projects the acquisition to be EPS neutral, potentially mildly favorable, in the first year (FY26) and targets a strong 20-22% Return on Capital Employed (ROCE) by FY29-30, indicating a clear and attractive path to value creation for the significant GBP 150 million investment.
Future Growth Prospects
Catalysts (next 12-24 months)
Swipe or use arrows to browse all triggers.
Commissioning of 1,500 new beds in flagship Indian regions over next 3-4 years.
Timeline
- in progressFY26 P · ppt
Greenfield/Inorganic Capex FY26 (P) ₹4,240 Mn, FY26 (A) ₹955 Mn
- in progressFY27 · ppt
South-West Bangalore (Lease) 100 beds, Completion FY27; Structural work completed, MEP and interior work in progress.
Show full timeline (4)
- in progressFY28 · ppt
HSR, Rajarhat, Central Bangalore, Raipur for completion FY28
- in progressFY29 · ppt
South Bangalore (Greenfield) 350 beds, Completion FY29
Supporting evidence
• FY25 · ar · planned a CAPEX investment of INR 8,000 Mn for the fiscal year FY26 for the Group with major allocations towards greenfield projects, which will result in addition of 1,500 beds in the next 3 to 4 years.
Show evidence (2)
• Q3 FY26 · ppt · Total Bed Capacity Target: 7,600+ (from current 5,750 on 31-Dec-25)
Increased high-end robotic cardiac surgeries and expanded oncology services.
• Q3 FY26 · ppt · 244 robotic cardiac surgeries (35% increase QoQ) performed at NICS, Bangalore in Q3 FY26.
Show evidence (2)
• Q3 FY26 · concall · oncology and cardiac will account for more than half of our revenue going forward. Our oncology could go up possibly another 20% depending on the years going forward.
Expansion of Integrated Care and Insurance business to new geographies and SME markets.
• Q3 FY26 · concall · We have expanded to Kolkata and we will be slowly expanding to Raipur as well. Over time, we want to operate our insurance plan in all the markets where we have a significant physical presence.
Show evidence (2)
• Q3 FY26 · ppt · YTD Gross Written Premium ₹240 Mn in Q3 FY26, 49.7% YoY.
Integration of UK-based Practice Plus Group Hospitals, applying technology and operational efficiencies.
Timeline
- commissionedNov 2025 · ppt
Q3 FY26 (as per India financial year) numbers are considered from 6th November 2025 i.e., from the effective date of acquisition.
- in progressnext 4-12 months · concall
We've always hoped that such an operation would take about four quarters or one year [to breakeven for Birmingham]. It's been half that time.
Show full timeline (3)
- in progressnext few quarters · concall
In terms of how hard it is to roll these out, we'll know in a few quarters. But so far, we're fairly optimistic. I don't think there's any negative surprise, thankfully, yet.
Supporting evidence
• Acquisition Concall · acq_concall · Acquired for ~GBP 183 million* implying 9.2x FY25E EV/EBITDA multiple... Target growing at 12% Y-o-Y over last 5Y.
Show evidence (2)
• Q3 FY26 · concall · We do expect that the path will be flat or mildly positive, like we had indicated earlier. So therefore, we do continue to hold our position that this acquisition will be EPS neutral for the group.
Variant perception
Non-consensus viewConsensus might be under-appreciating the sustained margin expansion potential in core India operations and the long-term accretive nature of the UK acquisition despite initial consolidated margin dip.
- India's core hospital business to maintain 150-200 bps YOY margin expansion, driven by high-end robotic surgeries and payor mix optimization.
Show more (1)Hide extras
- UK acquisition's breakeven (target 4-12 months for Birmingham) accelerated by technology integration and private patient growth.
- Increased competition in North India and Sarjapur area may dilute volumes and delay ramp-up of new capacity.
Show more (1)Hide extras
- Regulatory changes in payor schemes or further capping on drug reimbursement could pressure India's realization rates.
Quick takeaway
Sustained India hospital growth through payor mix and high-end procedures.
Risk watch: Initial dilution from UK acquisition on consolidated margins (21.7% in Q3 FY26 vs 24.4% in Q3 FY25).
Show details (2 drivers, 2 risks)Hide details
Drivers
- Sustained India hospital growth through payor mix and high-end procedures.
- Cayman growth stabilizing, UK acquisition progressing towards EPS neutrality.
Risks
- Initial dilution from UK acquisition on consolidated margins (21.7% in Q3 FY26 vs 24.4% in Q3 FY25).
- Increased competition in India's Northern cluster impacting volumes.
Quick takeaway
Faster than expected integration of UK operations & technology platform driving efficiencies.
Risk watch: Macroeconomic headwinds impacting consumer spending on private healthcare.
Show details (2 drivers, 2 risks)Hide details
Drivers
- Faster than expected integration of UK operations & technology platform driving efficiencies.
- Significant market share gains in private payor mix in UK and India.
Risks
- Macroeconomic headwinds impacting consumer spending on private healthcare.
- Delay in regulatory approvals for new India capacity.
Quick takeaway
Prolonged gestation period for new India hospitals due to competition/slow ramp-up.
Risk watch: Unforeseen regulatory changes in India or UK impacting pricing/reimbursement.
Show details (2 drivers, 2 risks)Hide details
Drivers
- Prolonged gestation period for new India hospitals due to competition/slow ramp-up.
- UK acquisition remaining dilutive to profitability longer than expected for Birmingham unit.
Risks
- Unforeseen regulatory changes in India or UK impacting pricing/reimbursement.
- Higher than expected staff costs or operational overheads.
Quick takeaway
Sustained India hospital growth through payor mix and high-end procedures.
Risk watch: Initial dilution from UK acquisition on consolidated margins (21.7% in Q3 FY26 vs 24.4% in Q3 FY25).
Show details (2 drivers, 2 risks)Hide details
Drivers
- Sustained India hospital growth through payor mix and high-end procedures.
- Cayman growth stabilizing, UK acquisition progressing towards EPS neutrality.
Risks
- Initial dilution from UK acquisition on consolidated margins (21.7% in Q3 FY26 vs 24.4% in Q3 FY25).
- Increased competition in India's Northern cluster impacting volumes.
Quick takeaway
Faster than expected integration of UK operations & technology platform driving efficiencies.
Risk watch: Macroeconomic headwinds impacting consumer spending on private healthcare.
Show details (2 drivers, 2 risks)Hide details
Drivers
- Faster than expected integration of UK operations & technology platform driving efficiencies.
- Significant market share gains in private payor mix in UK and India.
Risks
- Macroeconomic headwinds impacting consumer spending on private healthcare.
- Delay in regulatory approvals for new India capacity.
Quick takeaway
Prolonged gestation period for new India hospitals due to competition/slow ramp-up.
Risk watch: Unforeseen regulatory changes in India or UK impacting pricing/reimbursement.
Show details (2 drivers, 2 risks)Hide details
Drivers
- Prolonged gestation period for new India hospitals due to competition/slow ramp-up.
- UK acquisition remaining dilutive to profitability longer than expected for Birmingham unit.
Risks
- Unforeseen regulatory changes in India or UK impacting pricing/reimbursement.
- Higher than expected staff costs or operational overheads.
Story of the Stock - Top Strategies
UK Acquisition - Practice Plus Group
Acquisition of UK's 5th largest private healthcare network for ~GBP 183 million, targeting 12% Y-o-Y revenue growth and 12.5% EBITDA CAGR.
Show more
Acquiring Practice Plus Group (PPG) to leverage learnings from Cayman for a larger addressable market and diversify international revenues. The deal implies a 9.2x EV/EBITDA multiple on FY25E.
Evidence
Integrated Care Expansion
Significant ramp-up in Integrated Care business, starting formal sales in January, with positive response and expected breakeven by end of FY26 or Q1 FY27.
Show more
Expanding Integrated Care business, which has a different margin profile than hospitals, to create a safe lock-in with customers and a non-volatile earning stream.
Evidence
Digital Transformation & Technology Adoption
Investing in digital transformation to improve operational efficiencies, reduce turnaround time, and enhance patient outcomes, with initiatives like Athma platform and AI insights.
Show more
Focus on digital initiatives to streamline processes, improve operational efficiencies, and enhance patient experience, including mobile apps, EMR, and AI for ICU care.
Evidence
Business Segments
Community
Share your view anonymously. Comments are public and sorted newest first.
Anonymous post · 1500 characters left